Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial.

However, in patients with T2DM, those treated with volixibat showed a trend towards increased levels of serum HDL-C, decreased levels of serum triglycerides and reductions in fasting glucose levels, suggesting improvements in both lipid and glucose homeostasis.

also in 53,322 other papers

Post-MTT, there were no consistent or nominally significant differences between the volixibat and placebo groups in LS mean E max , AUC (0–3) or rAUC (0–3) for insulin or C-peptide; for C-peptide, there was a trend towards lower values in the volixibat groups compared with the placebo group (Table 5 and Additional file 2 : Table S1).

also in 7,732 other papers